Provided by Tiger Trade Technology Pte. Ltd.

Insulet

139.61
-0.9900-0.70%
Volume:133.66K
Turnover:18.63M
Market Cap:9.67B
PE:26.36
High:140.38
Open:140.38
Low:138.51
Close:140.60
52wk High:354.88
52wk Low:126.40
Shares:69.26M
Float Shares:69.07M
Volume Ratio:0.33
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.30
EPS(LYR):3.48
ROE:26.02%
ROA:9.71%
PB:6.80
PE(LYR):40.13

Loading ...

Dexcom Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 02

Insulet to Report Q2 2026 Results, Host Conference Call

Reuters
·
Jul 01

Press Release: Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026

Dow Jones
·
Jul 01

Insulet (PODD) After Russell Index Inclusion With Fair Value Still In Focus

Simply Wall St.
·
Jul 01

Dexcom Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Jul 01

20 Stocks in the S&P 500 That Plunged the Most in 2026's First Half

Dow Jones
·
Jun 30

Insulet Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 26

Insulet Names Ex-idexx CEO Jay Mazelsky to Board, Effective July 1, 2026

Reuters
·
Jun 25

Insulet Announces Appointment of Jonathan J. Mazelsky to Its Board of Directors

THOMSON REUTERS
·
Jun 25

Dexcom Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jun 25

Insulet initiated with a Buy at Deutsche Bank

TIPRANKS
·
Jun 24

Can Insulet’s (PODD) Closed-Loop Type 2 Data Reframe Its Long-Term Diabetes Tech Narrative?

Simply Wall St.
·
Jun 23

Deutsche Bank Initiates Coverage on Insulet With Buy Rating, $190 Price Target

MT Newswires Live
·
Jun 23

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pfizer (PFE) and Insulet (PODD)

TIPRANKS
·
Jun 23

Insulet Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 23

Insulet Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 19

Insulet Corp. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Jun 18

Insulet Corp. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Jun 16

Piper Sandler Keeps Their Buy Rating on Insulet (PODD)

TIPRANKS
·
Jun 15

Insulet Is Maintained at Buy by Truist Securities

Dow Jones
·
Jun 12